Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives
Graves’ orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves’ disease. It often impairs patients’ qu ality of life, causing severe social and psychological sequelae. Intravenous glucocorticosteroids is currently the mainstay of therapy, but the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2022-11-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0303.xml |
| _version_ | 1797988005880791040 |
|---|---|
| author | Jakub Supronik Małgorzata Szelachowska Adam Kretowski Katarzyna Siewko |
| author_facet | Jakub Supronik Małgorzata Szelachowska Adam Kretowski Katarzyna Siewko |
| author_sort | Jakub Supronik |
| collection | DOAJ |
| description | Graves’ orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves’ disease. It often impairs patients’ qu ality of life, causing severe social and psychological sequelae. Intravenous glucocorticosteroids is currently the mainstay of therapy, but the efficacy is often underwhelming and recurrence rate is high. For many years, clinicians have been searching for new methods of treatment. Rituximab (RTX) is a chimeric monoclonal antibody targeted against CD20 w hich is a surface antigen present on B cells. It is frequently used to treat non-Hodgkin’ s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, or various types of vasculitis. Numerous clinical trials employing RTX in the treatment of GO have shown promising results. RTX is currently considered to be a valid second-line treatment option in patients unresponsive to previous interventions or in disease reactivation. This revi ew summarizes the available literature on this topic, including two largest, randomized, co ntrolled studies. Potential benefits, as well as the limitations of RTX therapy, are discuss ed. |
| first_indexed | 2024-04-11T07:55:54Z |
| format | Article |
| id | doaj.art-77421d22ae924c1ba59d79da67481c03 |
| institution | Directory Open Access Journal |
| issn | 2049-3614 |
| language | English |
| last_indexed | 2024-04-11T07:55:54Z |
| publishDate | 2022-11-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-77421d22ae924c1ba59d79da67481c032022-12-22T04:35:55ZengBioscientificaEndocrine Connections2049-36142022-11-011112113https://doi.org/10.1530/EC-22-0303Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectivesJakub Supronik0Małgorzata Szelachowska1Adam Kretowski2Katarzyna Siewko3Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, PolandDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, PolandDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland; Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, PolandGraves’ orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves’ disease. It often impairs patients’ qu ality of life, causing severe social and psychological sequelae. Intravenous glucocorticosteroids is currently the mainstay of therapy, but the efficacy is often underwhelming and recurrence rate is high. For many years, clinicians have been searching for new methods of treatment. Rituximab (RTX) is a chimeric monoclonal antibody targeted against CD20 w hich is a surface antigen present on B cells. It is frequently used to treat non-Hodgkin’ s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, or various types of vasculitis. Numerous clinical trials employing RTX in the treatment of GO have shown promising results. RTX is currently considered to be a valid second-line treatment option in patients unresponsive to previous interventions or in disease reactivation. This revi ew summarizes the available literature on this topic, including two largest, randomized, co ntrolled studies. Potential benefits, as well as the limitations of RTX therapy, are discuss ed.https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0303.xmlgraves’ orbitopathyrituximabthyroid eye diseasegraves’ disease |
| spellingShingle | Jakub Supronik Małgorzata Szelachowska Adam Kretowski Katarzyna Siewko Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives Endocrine Connections graves’ orbitopathy rituximab thyroid eye disease graves’ disease |
| title | Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives |
| title_full | Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives |
| title_fullStr | Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives |
| title_full_unstemmed | Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives |
| title_short | Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives |
| title_sort | rituximab in the treatment of graves orbitopathy latest updates and perspectives |
| topic | graves’ orbitopathy rituximab thyroid eye disease graves’ disease |
| url | https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0303.xml |
| work_keys_str_mv | AT jakubsupronik rituximabinthetreatmentofgravesorbitopathylatestupdatesandperspectives AT małgorzataszelachowska rituximabinthetreatmentofgravesorbitopathylatestupdatesandperspectives AT adamkretowski rituximabinthetreatmentofgravesorbitopathylatestupdatesandperspectives AT katarzynasiewko rituximabinthetreatmentofgravesorbitopathylatestupdatesandperspectives |